Size:
4
Pay in installments of $6.12 with
,
and
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 4 - Jul 9
Promo Codes Available:
For Your Every Summer RSVP, with Code: SUMMER15
Description
blue midi dress BODYCON COLLECTION Royal Blue One Shoulder Bandage Midi Dress for Women, XLLELA ONE SHOULDER BANDAGE DRESS IN ROYAL BLUE The Lela Bandage Midi Dress in Royal Blue is perfect for any special event with flattering one sleeve with statement bow detailing, full length zip and below knee finish. More on the plus size? Our bodycon dresses range in all sizes, so get that bodycon wardrobe you've always wanted, today. FEATURES & CARE Midi Length, approx 105cm Premium Polyester Nylon and Rayon One Shoulder Bow Detailing Gentle Machine
LELA ONE SHOULDER BANDAGE DRESS IN ROYAL BLUE
The Lela Bandage Midi Dress in Royal Blue is perfect for any special event with flattering one sleeve with statement bow detailing, full length zip and below knee finish. More on the plus size? Our bodycon dresses range in all sizes, so get that bodycon wardrobe you've always wanted, today.FEATURES & CARE
-Midi Length, approx 105cm
-Premium Polyester Nylon and Rayon
-One Shoulder
-Bow Detailing
-Gentle Machine Wash
TOP REVIEWS
"Oh, this dress is gorgeous! Beautiful evening dress, it's perfect"
"Beautiful!! Fast shipping and very good quality. Highly recommended!"
"Absolutely love this look on me. I'm a UK size 10 and always order a medium"
Shipping Notes
- Free Standard Shipping on $100+ Orders to the USA.
- Except Preorder products are shipped in 48 hours.
- Delivery to the USA:
- Standard Shipping : 3-10 business days
- If time is of the essence, please consider selecting expedited delivery for faster service.
Exchange/Return Notes
- We offer a 30-day return/exchange service after receiving.
- Final sale items are not eligible for returns or exchanges.
- To process your return/exchange, please contact us at [email protected]
- Please click here for more details>>> Return & Exchange Policy
4.6 ★★★★★
Based on 2357 reviews
Sort
Product Reviews
★★★★★ 3
No Answers Provided to Case Studies
Format: Paperback
The cases are helpful; however, realize that there are NO answers whatsoever to the questions presented in the cases--not a huge problem I suppose, b/c you can google everything, but certainly an annoyance. (esp. when there are multiple possible answers. The author states in the foreword that some of the cases are real; in which case, why not provide the justification presented in the patient's chart as to why that patient takes a particular drug, esp. considering that you may take a drug for its side effects rather than its therapeutic effect. . .anyhow. . )
I think if the author provided at least SOME insight/guidance to the cases that it would be much more helpful, but until then, I'm skeptical as to why others gave this book 5 stars.
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on July 23, 2016
★★★★★ 5
... for a Patho class and thought it was a great resource. My group had hypertension and it was ...
Format: Paperback
Used this for a Patho class and thought it was a great resource. My group had hypertension and it was really good about giving an overview of the disease without overwhelming you with information. Some of the studies were obvious as to why the disorder occurred but in those cases it helped link body systems and show interactions.
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on June 19, 2015
★★★★★ 5
Brand new
Format: Paperback
Brand new, fast delivery!
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on April 8, 2024
★★★★★ 5
Great condition
Format: Paperback
Awesome condition for the money.
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on September 15, 2023
★★★★★ 5
Wish there were more, love it
Format: Paperback
Really like this book. It has questions and adjoined answers. Although not set up like traditional NCLEX books. Great study guide wish there were more of it.
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on April 11, 2026